Six Flags Entertainment (SIX) Forms $63.77 Double Top; 683 Capital Management Has Upped By $900,000 Its Galmed Pharmaceuticals LTD (GLMD) Position

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Logo

683 Capital Management Llc increased Galmed Pharmaceuticals Ltd (GLMD) stake by 18.21% reported in 2017Q4 SEC filing. 683 Capital Management Llc acquired 100,000 shares as Galmed Pharmaceuticals Ltd (GLMD)’s stock declined 42.08%. The 683 Capital Management Llc holds 649,295 shares with $5.94M value, up from 549,295 last quarter. Galmed Pharmaceuticals Ltd now has $95.08M valuation. The stock decreased 1.44% or $0.09 during the last trading session, reaching $6.16. About 109,239 shares traded or 155.56% up from the average. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 11.79% since May 17, 2017 and is uptrending. It has outperformed by 0.24% the S&P500.

Six Flags Entertainment Corporation (SIX) formed double top with $66.32 target or 4.00% above today’s $63.77 share price. Six Flags Entertainment Corporation (SIX) has $5.33B valuation. The stock increased 0.71% or $0.45 during the last trading session, reaching $63.77. About 1.29M shares traded or 30.56% up from the average. Six Flags Entertainment Corporation (NYSE:SIX) has risen 3.06% since May 17, 2017 and is uptrending. It has underperformed by 8.49% the S&P500.

Analysts await Six Flags Entertainment Corporation (NYSE:SIX) to report earnings on July, 25. They expect $0.93 EPS, up 57.63% or $0.34 from last year’s $0.59 per share. SIX’s profit will be $77.70 million for 17.14 P/E if the $0.93 EPS becomes a reality. After $-0.74 actual EPS reported by Six Flags Entertainment Corporation for the previous quarter, Wall Street now forecasts -225.68% EPS growth.

Among 16 analysts covering Six Flags Entertainment (NYSE:SIX), 12 have Buy rating, 1 Sell and 3 Hold. Therefore 75% are positive. Six Flags Entertainment had 39 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Thursday, April 26 by FBR Capital. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, October 11. The firm earned “Outperform” rating on Tuesday, June 20 by Wedbush. The rating was initiated by Stifel Nicolaus with “Buy” on Friday, April 21. Oppenheimer maintained it with “Outperform” rating and $65 target in Wednesday, April 6 report. On Monday, January 8 the stock rating was maintained by Wedbush with “Buy”. The firm has “Buy” rating given on Tuesday, July 18 by Oppenheimer. The firm has “Buy” rating given on Wednesday, June 21 by Oppenheimer. The rating was maintained by FBR Capital with “Outperform” on Thursday, October 27. On Tuesday, August 23 the stock rating was initiated by Hilliard Lyons with “Long-Term Buy”.

Among 5 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galmed Pharmaceuticals Ltd had 9 analyst reports since August 14, 2015 according to SRatingsIntel. Roth Capital maintained Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) on Thursday, August 13 with “Buy” rating. Maxim Group upgraded the stock to “Buy” rating in Thursday, March 15 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, March 28. Maxim Group maintained it with “Buy” rating and $1400 target in Monday, July 31 report. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) earned “Hold” rating by Maxim Group on Wednesday, February 14. The firm earned “Buy” rating on Tuesday, August 8 by H.C. Wainwright.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ratings Chart